Abstract: Objective To investigate the relationship between XRCC1 Arg194Trp and Arg399Gln polymorphism genotype and chemosensitivity to platinum-based in ovarian cancer.
Methods Polymerase chain reactionrestriction fragment length polymorphism （PCR-RFLP） analysis was performed to detect 82 cases of XRCC1 Arg194Trp and Arg399Gln polymorphism genotype after platinumbased chemotherapy drugs up to six cycles of ovarian cancer. And the association between the two genes sites were analyzed.
Results XRCC1 Arg194Trp had three genotypes， namely Arg／Arg， Arg／Trp， Trp／Trp， and frequency distribution was 47.6％， 43.9％， 8.5％， respectively. XRCC1 Arg399Gln had three genotypes， namely Arg／Arg， Arg／Gln， Gln／Gln， and frequency distribution was 25.6％， 40.2％， 34.1％， respectively. There were statistically significant difference of different genotypes in FIGO stage and age group （P＜0.05）. The genotypes existed difference between the group of sensitive to chemotherapy and nonsensitive to chemotherapy （P＜0.05）. XRCC1 Arg194Trp Trp／Trp genotype and Arg399Gln Gln/Gln genotype were easier to resistance to platinum drug compared with the Arg／Arg genotype， the odds ratio could be increased by 13.50 （95％CI： 1.461-124.739） times and 7.65 （95％CI： 2.012-29.088） times, respectively. While carrying 194Arg／Trp and 399Gln／Gln patients have 84.62％ of non-sensitive to chemotherapy（OR=22.00，95％CI：2.534～190.998；P＜0.05）. Conclusion Polymorphism in the XRCC1 Arg194Trp and Arg399Gln may have significant impact on the response of ovarian cancer to platinum-based chemotherapy； and the two gene sites have combined effect.